1. Romero P, Dunbar PR, Valmori D, Pittet M, Ogg GS, Rimoldi D, et al. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med. 1998;188:1641–50.
2. Valmori D, Scheibenbogen C, Dutoit V, Nagorsen D, Asemissen AM, et al. Circulating tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(−) effector subset exerting ex vivo tumor-specific cytolytic activity. Cancer Res. 2002;62:1743–50.
3. Jaume JC. Endocrine Autoimmunity. In: Greenspans’ Basic and Clinical Endocrinology, edn 9, Eds GC Gardner & DM Shoback. New York: McGraw-Hill Medical; 2017. P. 27–46.
4. Korman A, Yellin M, Keler T. Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodies. Curr Opin Investig Drugs. 2005;6:582–91.
5. Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006;354:709–18.